Does impaired renal function predict adverse outcomes in patients with heart failure, and does baseline eGFR modify the beneficial effect of candesartan?
Impaired renal function is a strong independent predictor of adverse outcomes in heart failure across the LVEF spectrum, but does not diminish the therapeutic benefit of candesartan.
Impaired renal function is independently associated with heightened risk for death, cardiovascular death, and hospitalization for heart failure in patients with CHF with both preserved as well as reduced LVEF. There was no evidence that the beneficial effect of candesartan was modified by baseline eGFR.
Hillege et al. (Mon,) studied this question.